Clinical Trials Spotlight - Lupus Nephritis

Icon of a kidneyAmbulatory & Chronic Disease CTSU Support Exciting New Trial Studying Lupus Nephritis

The Ambulatory & Chronic Disease CTSU is supporting a trial studying Lupus Nephritis led by Principal Investigator, Patricia Cagnoli, MD. Sponsored by Bristol-Myers Squibb and part of The Paisley Study, Dr. Cagnoli is evaluating the safety and effectiveness of an investigational drug versus placebo in regards to kidney function in subjects with Lupus Nephritis. 

Lupus Nephritis is a kidney disease caused by the autoimmune disease Systemic Lupus Erythematous (SLE) and results in the inflammation of the kidneys. It is estimated that 1.5 million Americans are currently living with SLE and of those, nearly 60% will be diagnosed with Lupus Nephritis. Lupus Nephritis may lead to kidney failure and the need for dialysis or kidney transplant. 

“Lupus Nephritis is one of the most debilitating manifestations of systemic lupus, with approximately 10% of patients progressing to end-stage renal disease,” said Tiffany McDonald, Clinical Research Coordinator. “New therapies are urgently needed, and we are very excited to work on this study looking at potential therapy for Lupus and Lupus Nephritis.”

The Paisley Study is still actively recruiting subjects. To learn more about The Paisley Study, click here and here.



Contact us at

The Molecular & Behavioral Neuroscience Institute, 205 Zina Pitcher Place, Ann Arbor, MI 48105

A list of CTSO-CTSU contacts are available in the Personnel Directory.